Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ: CTNM ) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company s